Fact CheckerSign in

NCT07805681Not yet recruiting

Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma

A Multicenter Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test, PancreaSure, for Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC) Detection in High-Risk Surveillance Program

Source: ClinicalTrials.gov · Last updated 4 Sept 2026

Brief summary (registry, in English)

The goal of this observational registry is to examine the changes made to pancreatic cancer surveillance management following the real-world clinical use of PancreaSure testing among individuals at increased risk for pancreatic ductal adenocarcinoma. The main question it aims to answer is, does surveillance management and intent change following the return of PancreaSure binary results.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
400 (estimated)
First submitted
24 Apr 2026
Start date
Sept 2026
Primary completion date
Jan 2028
Lead sponsor
Immunovia, Inc.
NCT number
NCT07805681

What you commit to

  • Study type: Observational
  • Planned participants: 400
  • From Sept 2026 to the primary completion date, Jan 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior diagnosis of PDAC or other active malignancy within 3 years (except non-melanoma skin cancer).

Other

  • Participation in interventional investigational studies that may bias test use.
  • Inability or unwillingness to comply with follow-up schedule.

Who the study is looking for

  • Able to provide informed written consent and complete the survey in English or Spanish
  • \>45 years of age
  • PancreaSure ordered as part of routine clinical care.
  • At elevated risk for PDAC or is deemed appropriate for PDAC early detection testing based on:
    • Family history in ≥ 2 first-degree relatives, or
    • Known pathogenic germline mutation (BRCA1/2, CDKN2A, PALB2, ATM, STK11, PRSS1), or
    • Pancreatic cystic lesion, or
    • New-onset diabetes with additional risk factors, or
    • Clinician discretion

Age in the registry: 45 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.